Adolor — Conference call on Entereg Study 014 findings, April 9, 2007
17 slides from Adolor's conference presentation, Apr 10, 2007

Slide 1: oration. All rights reserved.
Exhibit 99.2 © 2007 Adolor Corporation. All rights reserved.

Slide 2: Entereg (alvimopan) Preliminary Findings from Study 014 and Clinical Development Program Update
Entereg ® (alvimopan) Preliminary Findings from Study 767905/014 and Clinical Development Program Update April 9, 2007

Slide 3: Safe Harbor Statement
Safe Harbor Statement This oral presentation and the questions and answers that follow contain forward-looking statements, including, but not limited to, statements + our ability to receive FDA approval for our NDA in POI for Entereg® + our collaborator’s plans for development of Entereg® in of \duc

Slide 4: Study 014 Objectives
Primary Objective: To compare alvimopan with placebo for long-term safety and tolerability in patients taking opioids for chronic non cancer pain with opioid induced bowel dysfunction Secondary Objectives: To compare alvimopan with placebo for constipation related quality of life assessments Additio

Slide 5: Study Design
Study 014 Design *Treatment clinic visits at Months 1, 3, 6, 9 & 12 2 week Follow-Up Period 1 week Screening Period 12 month Treatment Period* Day -7 Screening Placebo Day 1 Randomization Month 12 Treatment Completed 2 Weeks Post Treatment Follow-Up 0.5mg twice daily (bid) Randomized (2:1), double-b

Slide 6: Study 014 Demographics
71 67 Overweight / Obese (%) 35/65 37/63 Female (%) / Male (%) 39 40 Tobacco Use (%) 29.9 29.5 BMI (kg/m 2 ) 91 87 Caucasian (%) Other Characteristics 51.9 Placebo (N=267) 53.8 Alvimopan 0.5mg BID (N=538) Mean Age (yrs) Demographics Study 014 Demographics

Slide 7: Study 014 Population
General Observations: Primary pain conditions – Back Pain, Arthritis, Fibromyalgia High prevalence at baseline medical conditions – Musculoskeletal, Cardiac, Psychiatric, Gastrointestinal High prevalence of CV and cancer risk factors – Smoking – Obesity – Hypertension – Hyperlipidemia Prevalent use

Slide 8: Study 014 – Most Frequent Adverse Events
Placebo Alvimopan (N = 267) (N = 538) Abdominal Pain 13% 16% Diarrhea 12% 14% Headache 11% 10% Nausea 11% 9% Vomiting 6% 7% Study 014 – Most Frequent Adverse Events

Slide 9: Cardiovascular Serious Adverse Events – OBD Studies
14 (2.60%) 7 (1.30%) Alvimopan (N=538) 5 (0.96%) 2 (0.38%) Placebo (N=523) 14 (1.18%) 1 (0.08%) Alvimopan (N=1190) 8 (1.01%) 2 (0.25%) Placebo (N=790) 28 (1.62%) 3 (1.12%) All Cardiovascular SAEs 8 (0.46%) - (0) Myocardial Infarction Alvimopan (N=1728) Placebo (N=267) Cardiovascular Serious Adverse

Slide 10: Cardiovascular Serious Adverse Events: Study Observations
Study 014 Observations Final results from Study 014 appear to show no additional serious cardiovascular adverse events following the interim analysis Cardiovascular adverse events reported in Study 014 were in patients with established or at high risk for cardiovascular disease. Risk factors include

Slide 11: Cardiovascular Serious Adverse Events - POI Studies
POI Studies* 2.45% 3.37% Other CV Adverse Events of interest 0.50% 0.51% Myocardial Infarction Alvimopan All Doses (N=2610) Placebo (N=1365) Event Cardiovascular Serious Adverse Events - POI Studies *Includes Studies 206, 213, 214, 302, 306, 308, 313, 314 and 001

Slide 12: Cardiovascular Serious Adverse Events
Does alvimopan, a mu opioid receptor antagonist, unmask Cardioprotective effects of opioids? Cardioprotective effects of opioids have been hypothesized to be mediated by delta receptors (preclinical models) Alvimopan and its metabolite bind with higher selectivity to the mu receptor over delta and k

Slide 13: Neoplasm Serious Adverse Events
1/1060 (0.09%) 0/465 Studies 011, 012, 013 4/538 (0.7%) 1/267 (0.4%) Study 014 Alvimopan All Doses Placebo Non-Cancer OBD Studies Study 014 - All Neoplasms*: Placebo 2 (0.7%) Alvimopan 15 (2.8%) Malignant Neoplasm Neoplasm Serious Adverse Events * benign, malignant, skin cancers and unspecified, inc

Slide 14: Neoplasm Events
Do opioid ligands inhibit the induction or proliferation of cancer? No clinically relevant findings with alvimopan in rodent carcinogenicity studies Literature Review – Opioid growth factor (OGF): An endogenous opioid peptide believed to mediate inhibition of cell proliferation and differentiation –

Slide 15: Quality of Life Assessment
PAC-QOL demonstrated a positive benefit of alvimopan compared to placebo Each subcategory of assessment also showed a positive difference compared to placebo – Physical discomfort – Psychosocial discomfort – Worries and concerns – Dissatisfaction Quality of Life Assessment

Slide 16: Alvimopan Development
GSK Study 015 Protocol withdrawn Study 684 (Extension of Study 008) stopped Adolor Study 228 (Combination Program) enrollment suspended POI Complete Response targeted 2Q 2007 Alvimopan Development

Slide 17: Adolor Corporation
Adolor Corporation 700 Pennsylvania Drive Exton, PA 19341 484-595-1500 © 2007 Adolor Corporation. All rights reserved.
Source: SEC EDGAR · 8-K filed Apr 10, 2007
More decks from Adolor Corp
Corporate Update (December 2007)14 slides · Dec 5, 2007
Technical Presentation (September 2006)17 slides · Sep 5, 2006
Technical Presentation (February 2006)17 slides · Feb 8, 2006
Technical Presentation (January 2004)22 slides · Jan 14, 2004
Technical Presentation (October 2003)12 slides · Oct 23, 2003
Technical Presentation (September 2003)21 slides · Sep 23, 2003